Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma

项目 3:体外建模以确定儿童疫苗反应、呼吸道传染病和哮喘易感性机制

基本信息

  • 批准号:
    10435043
  • 负责人:
  • 金额:
    $ 19.86万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-03-10 至 2027-02-28
  • 项目状态:
    未结题

项目摘要

Project Summary – Project 3 (PR3) Immune development in early life (IDEAL) is dynamic and growing evidence suggests that it impacts the risk for common undesirable clinical phenotypes including low vaccine responsiveness, and proneness to respiratory infection and/or asthma. However, little is known regarding precise mechanisms nor how to redirect immune development to more favorable phenotypes. The Precision Vaccines Program (PVP) at Boston Children’s Hospital (BCH) has developed cutting-edge human in vitro assays which model age related changes in leukocyte function- i.e., immune ontogeny and population (e.g. age)-specific effects and mechanisms of action of immunomodulatory agents, including metabolites, proteins, adjuvants and vaccines. Project 3 (PR3) will leverage human in vitro modeling to gain insight into signaling pathways that are relevant to the clinical phenotypes observed. Our published and unpublished preliminary data indicate that our sample-sparing human in vitro assay platforms can model innate and adaptive immune responses of infants and young children which vary by age and disease status. Our hypothesis is that our innate and adaptive in vitro modeling platforms can meaningfully interrogate molecular signaling pathways relevant to endotypes (disease sub-types) of clinical phenotypes such as vaccine responsiveness, respiratory infection and/or asthma. Our goal is to leverage our cutting-edge human in vitro assay systems to model human immune cell responses to infant vaccines as well as to confirm, assess and translate the pathways identified in PR1 and PR 2. We will achieve this goal by pursuing the following Specific Aims (SAs): SA1. Assess mechanisms underlying IDEAL endotypes. In this aim we will pursue molecular interrogation of pathways, biomarkers, metabolites discovered in PR1 and PR2. SA2. Identify immunomodulators that re-direct trajectories from unfavorable to favorable endotypes. We will model immune activation in response to agents capable of re- shaping immune endotypes, including agents that impact the relevant endotype-associated pathways identified in PR1 and PR2 . Overall, successful completion of PR3 will provide fresh insight into IDEAL in relation to vaccine responsiveness, infection and/or asthma proneness. This effort will provide mechanistic insight into IDEAL, help confirm and probe novel prognostic biomarkers and pathways identified in PR1 and PR2, and identify agents (e.g., proteins, metabolites, adjuvants, vaccines) that can redirect human infant leukocytes away from unfavorable endotypes associated with low vaccine responsiveness, respiratory infection and/or asthma and towards favorable trajectories and endotypes thereby advancing child health.
项目摘要-项目三(PR3)

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

OFER LEVY其他文献

OFER LEVY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('OFER LEVY', 18)}}的其他基金

Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma
生命早期的免疫发育 (IDEAL) 影响疫苗反应、呼吸道传染病和哮喘
  • 批准号:
    10435035
  • 财政年份:
    2022
  • 资助金额:
    $ 19.86万
  • 项目类别:
Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma
项目 3:体外建模以确定儿童疫苗反应、呼吸道传染病和哮喘易感性机制
  • 批准号:
    10589826
  • 财政年份:
    2022
  • 资助金额:
    $ 19.86万
  • 项目类别:
Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma
生命早期的免疫发育 (IDEAL) 影响疫苗反应、呼吸道传染病和哮喘
  • 批准号:
    10589800
  • 财政年份:
    2022
  • 资助金额:
    $ 19.86万
  • 项目类别:
Administrative Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma
管理核心:IDEAL 影响疫苗反应、呼吸道传染病和哮喘的易感性
  • 批准号:
    10435036
  • 财政年份:
    2022
  • 资助金额:
    $ 19.86万
  • 项目类别:
Administrative Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma
管理核心:IDEAL 影响疫苗反应、呼吸道传染病和哮喘的易感性
  • 批准号:
    10589801
  • 财政年份:
    2022
  • 资助金额:
    $ 19.86万
  • 项目类别:
IMPACC convalescent data collection, including Patient Reported Outcomes (PROs) and home visit sampling
IMPACC 恢复期数据收集,包括患者报告结果 (PRO) 和家访抽样
  • 批准号:
    10290547
  • 财政年份:
    2021
  • 资助金额:
    $ 19.86万
  • 项目类别:
IMPACC convalescent data collection, including Patient Reported Outcomes (PROs) and home visit sampling
IMPACC 恢复期数据收集,包括患者报告结果 (PRO) 和家访抽样
  • 批准号:
    10205742
  • 财政年份:
    2021
  • 资助金额:
    $ 19.86万
  • 项目类别:
Newborn cohorts to discover and validate biomarkers of neonatal vaccine immunogenicity
新生儿队列发现和验证新生儿疫苗免疫原性的生物标志物
  • 批准号:
    10323182
  • 财政年份:
    2020
  • 资助金额:
    $ 19.86万
  • 项目类别:
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity
识别新生儿疫苗免疫原性生物标志物的系统生物学
  • 批准号:
    10221106
  • 财政年份:
    2020
  • 资助金额:
    $ 19.86万
  • 项目类别:
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity
识别新生儿疫苗免疫原性生物标志物的系统生物学
  • 批准号:
    10265669
  • 财政年份:
    2020
  • 资助金额:
    $ 19.86万
  • 项目类别:

相似海外基金

Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination
通过新型 ASP-1 佐剂组合恢复年龄依赖性疫苗无反应
  • 批准号:
    10458553
  • 财政年份:
    2021
  • 资助金额:
    $ 19.86万
  • 项目类别:
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination
通过新型 ASP-1 佐剂组合恢复年龄依赖性疫苗无反应
  • 批准号:
    10220588
  • 财政年份:
    2021
  • 资助金额:
    $ 19.86万
  • 项目类别:
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination
通过新型 ASP-1 佐剂组合恢复年龄依赖性疫苗无反应
  • 批准号:
    10620718
  • 财政年份:
    2021
  • 资助金额:
    $ 19.86万
  • 项目类别:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
CoVPN 3005 - SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成人的功效、免疫原性和安全性
  • 批准号:
    10415762
  • 财政年份:
    2021
  • 资助金额:
    $ 19.86万
  • 项目类别:
Dissecting the mechanism of age-specific adjuvant synergy in vitro and in vivo
剖析年龄特异性佐剂体外和体内协同作用的机制
  • 批准号:
    9108575
  • 财政年份:
    2016
  • 资助金额:
    $ 19.86万
  • 项目类别:
CoVPN 3005: Efficacy, Immunogenicity, and Safety of Two SARS-CoV-2 Recombinant Protein Vaccines with Adjuvant in Adults 18 Years of Age and Older - LC 3
CoVPN 3005:两种 SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成人的功效、免疫原性和安全性 - LC 3
  • 批准号:
    10570739
  • 财政年份:
    2006
  • 资助金额:
    $ 19.86万
  • 项目类别:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
CoVPN 3005 - SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成人的功效、免疫原性和安全性
  • 批准号:
    10686595
  • 财政年份:
    2006
  • 资助金额:
    $ 19.86万
  • 项目类别:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of Two SARS-CoV-2 Recombinant Protein Vaccines with Adjuvant in Adults 18 Years of Age and Older
CoVPN 3005 - 两种 SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成年人的功效、免疫原性和安全性
  • 批准号:
    10581414
  • 财政年份:
    2006
  • 资助金额:
    $ 19.86万
  • 项目类别:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
CoVPN 3005 - SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成人的功效、免疫原性和安全性
  • 批准号:
    10579557
  • 财政年份:
    2006
  • 资助金额:
    $ 19.86万
  • 项目类别:
ADJUVANT TAMOXIFEN THERAPY IN OLD AGE
老年他莫昔芬辅助治疗
  • 批准号:
    2895539
  • 财政年份:
    1996
  • 资助金额:
    $ 19.86万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了